Evidence map›Paper›PMID 33494519›Full record

ArticleMolecules (Basel, Switzerland)2021

Andrea Spallarossa, Matteo Lusardi, Chiara Caneva, Aldo Profumo, Camillo Rosano, Marco Ponassi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrea SpallarossaDepartment of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy.
Matteo LusardiDepartment of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy.
Chiara CanevaDepartment of Pharmacy, University of Genova, Viale Benedetto XV, 3, 16132 Genova, Italy.
Aldo ProfumoIRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go R. Benzi 10, 16132 Genova, Italy.
Camillo RosanoIRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go R. Benzi 10, 16132 Genova, Italy.ORCID 0000-0003-2949-9215
Marco PonassiIRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go R. Benzi 10, 16132 Genova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyrimido-pyrimidine derivatives have been developed as rigid merbarone analogues. In a previous study, these compounds showed potent antiproliferative activity and efficiently inhibited topoisomerase IIα. To further extend the structure-activity relationships on pyrimido-pyrimidines, a novel series of analogues was synthesized by a two-step procedure. Analogues

Indexed as

Antineoplastic AgentsDNA Topoisomerases, Type IIMolecular Docking SimulationNeoplasm ProteinsNeoplasmsPoly-ADP-Ribose Binding ProteinsThiobarbituratesTopoisomerase II InhibitorsCell ProliferationFemaleHumansMCF-7 CellsAntineoplastic AgentsDNA Topoisomerases, Type IImerbaroneNeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsThiobarbituratesTOP2A protein, humanTopoisomerase II Inhibitorsantiproliferative agentsdocking simulationpyrimido-pyrimidine derivativesstructure activity relationships (SAR) study

Identifiers

PMID33494519
PMCPMC7866144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.